Category Archives: Pharmaceuticals

GenQual and R-Pharm collaborate to deliver predictive diagnostics for novel anti-IL-6 antibody for autoimmune diseases

Seattle, WA, San Francisco, CA and Moscow, Russia, 2016-May-25 — /EPR Network/ — R-Pharm and GenQual are pleased to announce a new collaboration focused on the development of novel predictive diagnostic tools in the area of Rheumatoid Arthritis and Autoimmune diseases.

The GenQual proprietary real-time PCR platform, when applied to the genes that are involved in the manifestation of several autoimmune diseases, allows us to detect and assess single nucleotide polymorphisms. Here, allelic determination is used as potential predictor of the treatment response by the novel anti-IL6 antibody, which is currently in development by R-Pharm.

GenQual Founder and CEO Jonathan Mirich said, “This partnership is exciting for GenQual as we advance in our goal to deliver predictive diagnostic tools for the treatment of autoimmune disorders. We are very excited about the possibilities in this space and are thankful to have quality partners in R-Pharm.”

R-Pharm CEO Vasily Ignatiev indicated the importance of the Autoimmune diseases as an area of the development and growth for R-Pharm, as well as the development of novel diagnostic tools aimed to increase the level of predictive response and efficiency of the upcoming treatment paradigm.

About GenQual
GenQual develops proprietary biomarker diagnostics for autoimmune and oncology indications.  Our personalized medicine products are designed to facilitate early disease detection and diagnosis, and to improve treatment approaches at the molecular level.  GenQual is a privately-held corporation based in Seattle, WA area, USA.

About R-Pharm
R-Pharm is a private Russian pharmaceutical company founded in 2001. It employs over 3,500 highly qualified specialists in 60+ branches. R-Pharm operates in Russia and CIS, USA, Germany, Japan, Turkey/MENA.

The company is involved in R&D, manufacturing (finished dosage forms, biotech and chemical APIs), marketing, sales and distribution of innovative pharmaceutical products in hospital/specialty care therapeutic areas.

R-Pharm collaborates with major international pharmaceutical companies and universities in the fields of drug discovery, development, clinical trials, manufacturing and commercialization.  The company operates several  GMP compliant manufacturing sites in Russia and Germany, research, BD/licensing and marketing affiliates in Japan, Germany, Turkey and US.

Marketed portfolio and pipeline features drugs used in oncology, hematology, autoimmune diseases, HIV, HCV, neurology, diabetes, cardiology, as well as antibiotics, contrast media and anesthesia agents.

Contact

R-Pharm
info@rpharm.ru
www.r-pharm.com/en/

 

GenQual

info@genqual.com
206.659.7825
www.genqual.com

European Pharmaceutical Review Launches Their New Media Planner for 2016

The publication European Pharmaceutical Review today announces the official launch of their new media planner for 2016.

Brasted, United Kingdom (November 17, 2015) — The publication European Pharmaceutical Review today announces the official launch of their new media planner for 2016.

“Throughout 2015, we have seen a very successful year unfold, with visitor numbers soaring by more than 230% and website registrations up by more than 78%. These figures show that our audience is becoming more relevant and larger in size to fit our clients’ needs” Graeme Cathie, Publisher, European Pharmaceutical Review.

Responses from their 2015 industry survey confirmed that:
• 95% of their community work in pharma, biotech or academia
• More than 91% of their visitors have influential purchasing power
• They have an online satisfaction rating of over 93%
• Over 78% of their print readers are involved in the decision making process

Each of their print issues goes to the top 25 pharmaceutical and top 25 biotechnology companies as well as the leading 25 life science academic institutions. Now that advertising opportunities are nearly sold out for 2015 both digitally and in print, European Pharmaceutical Review is now selling advertising and sponsorship across its portfolio for 2016.

About European Pharmaceutical Review
European Pharmaceutical Review is the leading publication and website for information on technologies in drug discovery and manufacturing. Published bi-monthly, every issue offers a high level of technical and business contributions from the world’s leading pharmaceutical companies and academic institutions, coupled with a variety of exciting new features including interviews, updates and profiles.

http://www.europeanpharmaceuticalreview.com

For further information, please contact:
Graeme Cathie, Publisher
European Pharmaceutical Review
T: +44 (0)1959 563311
E: gcathie@russellpublishing.com
W: http://www.europeanpharmaceuticalreview.com

Drug Target Review Launches Their New Media Planner for 2016

The publication Drug Target Review today announces the official launch of their new media planner for 2016.

Brasted, United Kingdom (November 16, 2015) — The publication Drug Target Review today announces the official launch of their new media planner for 2016.

“Throughout 2015, we have seen a very successful year unfold, with visitor numbers soaring by more than 400%. These figures show that our audience is becoming more relevant and larger in size to fit our clients’ needs” Nic Losardo, Publisher, Drug Target Review.

Responses from their 2015 industry survey confirmed that:
– More than 92% of their community work in Pharma, Biotec or Academia
– 75% of their visitors have influential purchasing power
– They have an online satisfaction rating of over 92%
– More than 73% of their print readers audience are involved directly in the purchasing decisions

Each of their print issues are sent to the top 25 pharmaceutical and top 25 biotechnology companies as well as the leading 25 life science academic institutions. Now that advertising opportunities are nearly sold out for 2015 both digitally and in print, Drug Target Review is now selling advertising space and sponsorship across its portfolio for 2016.

About Drug Target Review
Drug Target Review provides a voice for the drug discovery industry, promoting the latest research and developments, funding projects, and cutting-edge technological developments. We support academia, campus companies, tech transfers, research facilities and Pharma by creating a community with the goal of educating and sharing information and news. This community of diverse individuals is able to keep up to speed with research, news and funding as it happens through print, online and workshops.

http://www.drugtargetreview.com

For further information, please contact:
Nic Losardo, Publisher
Drug Target Review
T: +44 (0)1959 563311
E: nlosardo@russellpublishing.com
W: http://www.drugtargetreview.com

FIRST DIVERSITY MANAGER NAMED BY M. DAVIS & SONS, INC.

WILMINGTON, DE, June 18, 2015 — /REAL TIME PRESS RELEASE/ — M. Davis, the fifth generation woman-owned Industrial Contractor and Fabricator headquartered in Wilmington, DE has named Christina MacMillan its Manager of Supplier Diversity. Christina MacMillan will enhance the program by working with diverse vendors to help identify opportunities with M. Davis. This will enable M. Davis to continue promoting economic growth and community development through our diversity and inclusion initiatives while also expanding our current supplier base to include the best and brightest.

“Christina MacMillan will be able to pinpoint new vendors and suppliers and grow our diversity program,” says M. Davis CEO Peggy Del Fabbro. Mrs. MacMillan currently oversees the Accounting Department at M. Davis and has been vital to that role for over ten years. Complimenting her knowledge of diversity is her involvement with the Women’s Business Enterprise Council (WBEC) PA-DE-sNJ, Associated Builders and Contractors Delaware Chapter’s Diversity and Inclusion Committee, and the Emerging Leaders Council for the National Multiple Sclerosis Society Greater Delaware Valley Chapter. MacMillan received her BS in Business Administration and MBA from Goldey Beacom College.

From its beginnings as a tinsmith shop in the 1800’s to the current status as one of the larger businesses located in Wilmington, M. Davis continues to bring innovation to the construction industry.

About M. Davis & Sons, Inc.
M. Davis & Sons, Inc. is a merit shop mechanical and electrical contractor and fabricator located in Delaware serving customers in the Oil & Gas, Chemical, Pharmaceutical, Food, Beverage and Industrial markets. For more information contact Mike Kerwien via phone (302) 993-3303 or email Mike.Kerwien@mdavisinc.com. Visit our website at www.mdavisinc.com.

# # #

CONTACT: Mike Kerwien
302-993-3303
Mike.kerwien@mdavisinc.com

ViroCarb’s anti HIV Crowd Funding Campaign

Toronto, Canada, December 01, 2014 — /REAL TIME PRESS RELEASE NEWS/ — ViroCarb Inc. has launched a worldwide crowd funding campaign to promote the development of its new HIV infection inhibitor.

WORLD AIDS DAY – Make a donation to save lives from AIDS! Support new treatment development at: https://www.indiegogo.com/projects/funding-a-new-therapy-against-drug-resistant-hiv/x/9240077

Despite the great progress made in HIV/AIDS treatment, there is still an urgent need for new drugs, particularly for people who have had to abandon existing treatments due to HIV drug resistance and side effects.

The current treatment of HIV/AIDS involves the use of three or more drugs from five main general classes, used in combination. While this antiretroviral therapy (ART) has helped to reduced morbidity and mortality from AIDS, long term toxicity and the emergence and transmission of drug resistant HIV strains limit the effectiveness. Thus, despite therapy which can render this a chronic, rather than acute fatal infection, development of new drugs to prevent infection and overcome drug resistant strains, is increasingly urgent.

ViroCarb Inc. is developing a novel technology that addresses infections by drug resistant HIV strains. Developed from the identification of a new, natural resistance factor against HIV infection by scientists at SickKids and Canadian Blood Services, ViroCarb’s inhibitor works against a previously overlooked target on the virus to block HIV from entering human cells, the very first step in the infection. It works against all HIV strains.

Funds are needed to aid in moving forward to support preclinical studies; therefore ViroCarb Inc. has started an international crown funding campaign to carry out these HIV model studies needed before conducting clinical trials.
Please support this new way to block HIV.

Contact-Details: Dr. Mario Huesca
479 Simonston Boulevard.
Thornhill ON.
L3T 4M4 Canada

Facebook: https://www.facebook.com/ViroCarb;
Website: http://www.virocarb.com

MEDIA:

VIDEO:

Innovative Drug Discovery Business, Biosortia Pharmaceuticals, Lands Two Health Care Veterans

Kurt Dieck formerly SVP of Strategy and Business Execution at Cardinal Health, will lead early stage drug discovery business at Biosortia Pharmaceuticals. Dieck was named President and CEO in November 2012 and has quickly identified other key executives, including Dr. Guy Carter, former Natural Product head at Wyeth Pharmaceuticals, as his Chief Science Officer. In conjunction, other collaboration partners have joined the team, including NOAA (National Oceanic and Atmospheric Administration), NCI (National Cancer Institute) and key universities, to strategically accelerate the development of novel drug leads in the therapeutic areas of cancer, infectious diseases, inflammation and neurological disorders. Biosortia Pharmaceuticals has seen promising early results with dozens of novel compounds having already been requested, and are under evaluation with NCI and Eli Lilly.

Dieck has spent nearly 30 years in healthcare, including 18 years at Arthur Andersen as a global equity partner and then 10 years with Cardinal Health, a Fortune 20 public company, as a senior executive; there he worked with a broad spectrum of partners, including brand pharmaceutical manufacturers, throughout the supply chain. Dr. Guy Carter has over 30 years of experience working in pharmaceutical R&D, primarily in the discovery and development of microbial natural products. He previously was the leader of natural products drug discovery at Wyeth Research, as head of the Chemical Technologies Department.

“Kurt and Guy make a great team. Their complementary Pharma experiences and backgrounds create great opportunities to accelerate Biosortia’s objective to become the premier, aquatic natural products company with a primary focus in drug discovery,” says Ross Youngs, Biosortia’s Founder and Chairman. “Kurt and Guy bring a wealth of research and business experience along with deep industry relationships in building successful Pharma partnerships. Everyone involved with this young biotech is excited about the future.”

Industry observers have commented that late-stage R&D pipelines are not providing Pharma with the desired revenue growth the market is expecting. Therefore, large Pharma is evolving the way it performs R&D in order to optimize efficiency and to boost patent cliff defenses. These changes require shifting from relying solely on in-house chemistry-based R&D to acquiring and licensing external technologies and natural products based compounds in various stages of development. Biosortia’s ability to supply novel, highly active and potent compounds with drug-like characteristics will increase the productivity and success rate for Pharma as well as reduce the overall cost of the discovery process. The cost to discover, develop and launch a new drug is estimated to reach nearly $3B per drug by 2015. Biosortia’s business model is designed specifically to support Pharma’s needs.

“With nearly unlimited microorganisms (3.7 nonillion), the aquatic environment and its consortia represent an extraordinary opportunity…a new frontier, to access extremely potent and chemically diverse secondary metabolites with drug-like properties with unique mechanisms of action never researched before,” said Dieck. In describing the opportunity, Dieck goes on to say, “Biosortia is on the cutting edge of natural product discovery
and has the capabilities to deliver on its aspiration. Our powerful natural products research team, led by Dr. Guy Carter, in partnership with NOAA’s Dr. Peter Moeller, a leader in aquatic natural products research, has the experience and know-how to decipher the complex unexplored environment in a very efficient manner leveraging all the current state of the art instrumentation. The need for more efficient and effective approaches to drug discovery has never been more important. Biosortia’s innovative technologies, deep research skills and key relationships will efficiently provide thousands of unique natural products as candidates for drug discovery at a time when Pharma is in critical need for “high quality shots on goal.”

“Aquatic microbial consortia are a rich source of metabolically active organisms including microalgae, bacteria, fungi and their secondary metabolites,” states Carter. “Owing to the competitive nature of their habitat, chemical investigations of microbial consortia reveal unique structurally diversified natural products that are responsible for signaling and self-defense that have potential as therapeutics with novel mechanisms of action. Since they have been pre-optimized by nature, these compounds are typically closer to a drug candidate than a synthetic lead, thus requiring less optimization and shorter time when found as ‘hits’ in screening programs.”

The team has also focused on agreements with strategic collaboration partners as vital components to the strategy. Biosortia has recently entered into several collaboration agreements with NOAA, Analyticon and exclusive harvesting relationships, just to name a few. Several others will be advanced by the end of January. Biosortia’s cooperative research and development agreement (CRADA) with NOAA’s Center for Human Health Risk at Hollings Marine Laboratory provides a 5-year framework for research and development regarding the analysis and purification of novel bioactive compounds. According to NOAA’s Technology Partnerships Office, “Success will result in the commercial development of new and unique chemical compounds from the sea which have benefits to human health, either through disease prevention or new treatments for disease.”

Dr. Peter Moeller, NOAA’s Research Scientist who leads the Toxins Natural Products Program stated after analyzing fractions of Biosortia’s biomass, “Coupling NOAA’s mission of characterizing toxins affecting environmental and/or human health with Biosortia’s drug discovery focus turns one man’s toxin into another’s chemotherapeutic. The microorganisms analyzed in the Biosortia biomass identified more unique activity than I have seen in my 30 year career. The volumes achieved from a single harvest delivered an equivalent of 30 years of accumulation. This could materially change the landscape for natural products drug discovery research.”

As of December 31, 2012, Biosortia has identified more than 30 bioactive candidate compounds (hits) from a fresh water eutrophic lake consortium. Therapeutic areas of focus include treatments for cancer, infectious diseases, inflammation and neurological disorders. In addition, more than a dozen of its patent protected compounds are in initial evaluation stage within Eli Lilly’s Open Innovation Drug Discovery Program.

Dieck states, “Looking forward, it is with great optimism. We have a great team built around mutual respect, deep experience, and a desire to succeed and make a difference. We are aligning with the right partners and collaborators to execute our strategy with speed and discipline to provide Pharma with much high quality & diverse compounds vs. “me-too” drugs than they have had in the past 10 years. We are excited about what this company can accomplish, not only for its shareholders but also for the millions of people who have been diagnosed with various forms of chronic diseases who are looking for Pharma to identify better ways to help them extend their lives or live a more productive life. Biosortia can play a big role in identifying compounds that can help Pharma achieve these goals. I am looking forward to the challenge and opportunity to build an industry leading drug discovery company.”

# # #

About Biosortia Pharmaceuticals http://www.biosortia.com/: Biosortia Pharmaceuticals is a division of Algaeventure Systems (AVS). AVS is privately held company and are the inventors of the biomass harvesting technology. Biosortia has a proven and unique ability to obtain unculturable aquatic microorganism consortia from the natural environment in unprecedented quantities that allows its research team to perform direct study of vast quantities of new natural products (NPs), the foundation of most anti-infective agents such as antibiotics for the treatment of bacterial infections. Over 76% of cancer drugs are derived in some manner from NP.

If you’d like more information about the announcement or the company or to schedule an interview with Kurt Dieck, please call:

David Coho
Tel. 614-636-4850
Cell Phone: 614-325-9804
Email: dcoho@biosortia.com

 

3:30 Detox Diet launched by Matakana SuperFoods

The 3 day 3:30 Detox Diet combines 10 unique high-quality, super-ingredients which will set users on the path to better health, according to Matakana SuperFoods founder Kevin Glucina. “When I initially set out the foundations for the 3:30 Detox Diet I had many natural super-nutrient ingredients to choose from to help get the formula right. I narrowed that field down to the 10 most important ingredients for a detox diet. We included Cracked cell Chlorella which has recently been tested in Japanese clinical trials for reducing dioxin transfer from mothers milk to baby with remarkable results. Another ingredient is a long chain polysaccharide from Goji berry which has shown some protection for the liver in alcohol poisoning in rat studies. Both of the ingredients mentioned seem to reduce the impact of radiation exposure in human and rodent studies as well so there is a component in their antioxidant or phytochemical profile which is beneficial to our health.

The calorie intake from the 3:30 Detox Diet sachets, which are taken in a glass of water 4 times per day, is low but the nutrient content is very high. In the sachet formula I have included 7 ingredients which have some of the highest natural antioxidant levels in nature, as well as a powerful array of vitamins, minerals, electrolytes and phytochemicals. With the 3:30 Detox Diet we are restricting caloric intake over the 3 days but at the same time flooding the body with super-nutrients. The result will be a 3-day transformation of body chemistry, alkalinity and overall nutrient profile. Matakana SuperFoods have been a world-leader and first to market with many popular Superfood products. There are “world first” ingredients in the 3:30 Detox Diet as well. The ingredients contained within the12 capsules which participants will take each day, in addition to the 4 sachets, contain 2 organically-certified green alkalisers and a special new purified ingredient from Undaria seaweed called Fucoidan. Fucoidan is a leading new product in the world of nutriceuticals and clinical research in Asia and Australia has shown that Fucoidan aids the function of adult stem cells by making it easier for the stem cells to get to and aggregate at repair sites around the human body. Stem cell nutrition is the new horizon in the health food industry. Adult stem cells are the most important component of repair and maintenance of our immune system and body on every level and any natural substance that can support stem cell function has incredible potential for our health and wellbeing. This is the first time such a rare substance like organic Fucoidan has been used in a detox programme, and combined with all our other super-nutrient ingredients it will make the 3-day 3:30 Detox Diet one of the most advanced detox diets anywhere in the world.
http://www.matakanasuperfoods.com/ms/product-descriptions/156-330-detox-diet.html

Fucoidan – A Sulphated Polysaccharide of Undaria Seaweed

Contact Details: Email matakanasuperfoods@xtra.co.nz
http://www.matakanasuperfoods.com/ms/product-descriptions/156-330-detox-diet.html

Sprint Bioscience Strengthens Its Cancer Metabolism Portfolio

Sprint Bioscience, a Swedish company developing oncology therapeutics targeting cancer metabolism, announced today that it has raised money to strengthen its drug discovery portfolio.

The investment by Första Entreprenörsfonden and Almi Invest will enable the company to continue to build a pipeline of drug discovery projects within cancer metabolism.

“We are investing in Sprint Bioscience because we consider their entrepreneurial drive and their particular skills in drug development to be key success factors for the changing environment of the future pharmaceutical industry. Sprint Bioscience’s business strategy involves out-licensing or collaborating at an early stage of drug discovery to ensure that projects are developed with a focus on current and relevant market needs,” says Rune Nordlander, partner at Första Entreprenörsfonden.

Sprint Bioscience is a company founded by experienced drug hunters with an ambition to improve the drug discovery process. “We believe in small organisations with effective working procedures and collaborations throughout the sector,” says the company’s CEO and co-founder, Dr. Anders Åberg.

“Sprint Bioscience has developed an efficient, fragment-based drug discovery (FBDD) platform that can take parallel projects from initial idea to active molecules tested in cell-based systems in a very short time” Anders Åberg continues. Our goal is to align the early phase in the laboratory with pharmaceutical companies’ needs.

Targeting the metabolism in tumours provides exciting opportunities to develop drug therapies with novel mechanisms of action. This could be used to overcome the resistance that many cancer cells develop to current treatments.

###

For further information, please contact:

Anne-Marie Wenthzel, Director Business Development, Sprint Bioscience AB
Tel: +46-8-411 44 55
Cell Phone: +46-739 399 330
E-mail: amw@sprintbioscience.com

Anders Åberg, CEO and co-founder, Sprint Bioscience AB
Tel: +46-8-411 44 55
Cell Phone: +46-762 738 777
E-mail: anders.aberg@sprintbioscience.com

Contact Details: Sprint Bioscience
Teknikringen 38A
S-114 28 Stockholm
Sweden
Tel: +46 (0)8-411 44 55
info@sprintbioscience.com
www.sprintbioscience.com

Mettler-Toledo India Unveils New Meters for Liquid Density & Refractive Index Useful for Flavours & Fragrances Measurement

Mumbai, 24th May, 2012: Mettler-Toledo India, a wholly subsidiary of Mettler-Toledo Inc (NYSEMTD), announced the launching of its new LiquiPhysics™ Excellence instruments in India for density and refractive index determinations within the flavours and fragrances.

 

The new LiquiPhysics™ Excellence density and refractometers are simple to operate, sophisticated and versatile making them the ideal tools to deal easily with the high variety of products and parameters in the flavours and fragrances industry environment.

 

The One ClickTM user interface allows quick, simple and direct access to all routine tasks and provides clear user information with easy shortcut buttons to start routine tasks immediately. Every operator has a personalized home screen, shortcuts and operation language. A unique product/method concept fulfils even the most particular requirements without having to alter any settings.  Powerful sampling and automation units can completely automate measurement and cleaning procedures whilst sophisticated barcode functions conveniently input sample data and automatically ensure the right measurement method is always chosen.

 

The highly flexible concept, with full modularity, protects investments and facilitates the combination of density with refracto- colour-and/or pH-meters. This supports the simple expansion of measuring systems as and when additional needs arise enabling the simultaneous determination of multiple parameters. A smooth and seamless LIMS/SAP integration with LabX™ PC software organizes comprehensive sample lists containing all relevant data in order to fully automate quality control processes.

 

“The New LiquiPhysics™ instruments set a new standard in quality control of liquids. One can easily get all the required information such as pH, refractive Index, density and color at one glance by automation” said Mr. Pradeep Palshikar, Business Manager- AnaChem, Mettler-Toledo India.

 

Complete and secure traceability is only a click away with LabX™ PC software in order to easily, yet fully, comply with the many regulatory demands facing the flavour and fragrance industry. User identification and access control is performed in a most secure and fast way with biometric identification via a finger print reader. Sophisticated barcode functions quickly and conveniently input sample data and automatically ensure the right measurement method is always chosen. Comprehensive test and error detection functions, along with automatic adjustment verifications, offer tight security ensuring the instruments consistently provide precise results.

 

 

About Mettler-Toledo India:

 

Mettler-Toledo India Pvt. Ltd., a wholly subsidiary of Mettler-Toledo Inc. (NYSEMTD), started its operations in India in 1998. With its base in Mumbai and eleven branches across India, Mettler-Toledo India is a leading player catering to the demand of Indian industries for high-technology precision and analytical instruments used in various labs and automation processes.

 

Mettler-Toledo Inc. is a leading global supplier of precision instruments and is the world’s largest manufacturer and marketer of weighing instruments for use in laboratory, industrial and food retailing applications. The Company also holds top-three market positions in several related analytical instruments markets and is a leading provider of automated chemistry systems used in drug and chemical compound discovery and development. In addition, METTLER TOLEDO is the world’s largest manufacturer and marketer of metal detection systems used in production and packaging. Additional information about METTLER TOLEDO can be found on its website www.mt.com/liquiphysics

 

 

 

 

 

For more details, contact:

Sanjiv Arora

sanjiv@deeshapr.com

+91-22-32713357

Deesha Communications

http://www.deeshapr.com

Safeline Unveils HACCP Metal Detector with Modern Technology for Food Safety Standards in India

Mumbai, 25th February 2012: With ISO 22000 is set to become the global HACCP based international food safety standard, Mettler-Toledo Safeline, the leader in the field of industrial metal detection solutions, unveils its latest range of Profile metal detectors in India. The company offers the most advanced range of metal detection equipment in the world with a solution for every application.

 

Available in rectangular apertures for conveyorised applications, the “Profile” range is available in fixed, dual or multi and Selectable frequency configurations. The “Profile LS” variant of the range offers customers the freedom of choice to select the level of functionality required to suit their actual requirements. This is achieved through the selection of optional software which is designed to address specific business functions. The range is further complimented by the release of a new Profile ASN model which is designed to address applications where installation space is restricted. This comprehensive portfolio ensures that whatever the application, there is a Profile metal detection solution available.

 

Detection sensitivity levels have been enhanced to new heights with the development of a new software algorithm that significantly reduces the impact of signals present in the environment whilst simultaneously minimising the size of the signal (known as the product effect) given off by the product being inspected. The use of intelligent multi-channel technology also improves detection capability to a level previously unachievable.

 

Whilst sensitivity is the measure of metal detection performance, further customer focussed features have been developed to make the Profile an integral part of a user’s effective contamination prevention programme.

 

Ensuring compliance is achieved through meeting the demands of a HACCP programme, helping to increase on-line productivity, ensuring uptime is maximised and reducing costs are all key fundamental elements for food producers.

 

A unique Condition Monitoring system monitors key elements of the Profile metal detectors functionality and works on the basis that prevention is better than cure especially when measured against the costs of downtime. Many metal detectors in use today are designated as Critical Control Points (CCP’s). Should a problem occur with the metal detector during the inspection process, the production line should shut down until the problem is rectified as the CCP is no longer protected.

 

The cost associated with a line shutdown can be high. A metal detector that can advise when a fault occurs can be seen as beneficial as it allows for emergency service to be undertaken. However a metal detector that can give an advanced warning that a fault may be about to occur before it happens allows preventative maintenance to be scheduled when the line is out of service saving time and money.

 

“In order to maximize on quality and performance, METTLER TOLEDO has brought the unparallel metal detection solution, Profile Series, utilizing sophisticated software technology, Profile Series is very helpful in complying HACCP requirements and also for broader needs of External Food Safety regulations. Whether your products are wet, dry, hot, chilled or frozen, Profile Technology provides the ultimate solution in metal contaminant detection capability.” said Kailash Kale, Business Leader – Product Inspection. “All metal contamination including ferrous, non-ferrous and even the most difficult to detect non-magnetic stainless steels are readily identified, enabling them to be removed efficiently from the manufacturing process. Profile detectors in real sense provide a vital building block in helping the customers to establish improved processes and manufacturing efficiency thus increase productivity, to ensure uptime is maximized and also to reduce costly downtime.”

 

Continuing on the theme of maximising production uptime, Profile has been developed to address one of the biggest reported failure modes of any process or packing line equipment – that of operator error or unauthorised entry to the controls of equipment.

 

To address this issue, a secure personalised login system that allocates every user their personalised entry password has been created. To help navigation around the menu structure, operators can specify their own settings in a choice of 18 languages to ensure that when they log on, they can quickly and easily identify the operations they have been given access to. Every login to the detector is stored in an access log that can be viewed on the colour touch screen which reports the name of the operator and date and time when they logged onto the controls. This provides far greater levels of traceability and system security.

 

Using the latest in communications technology, Profile detectors can be configured to send email or text communications to various key people within the business reporting important events or issues. These could include missed performance verification tests, early warnings from the Condition Monitoring system.

 

It is even possible to configure the detector to communicate directly with Mettler Toledo service organisations to allow the fastest levels of response possible.

 

 

About Mettler-Toledo Safeline:

 

Mettler Toledo Safeline is the world’s leading supplier of metal detection and x-ray inspection solutions for the food and pharmaceutical industries. Together with Garvens Checkweighing, Mettler-Toledo Safeline forms the Product Inspection division of Mettler Toledo.

About Mettler-Toledo India:

Mettler-Toledo India Pvt. Ltd., a wholly subsidiary of Mettler-Toledo Inc. (NYSEMTD), started its operations in India in 1998. With its base in Mumbai and eleven branches across India, Mettler-Toledo India is a leading player catering to the demand of Indian industries for high-technology precision and analytical instruments used in various labs and automation processes.

 

Mettler-Toledo inc is a leading global supplier of precision instruments and is the world’s largest manufacturer and marketer of weighing instruments for use in laboratory, industrial and food retailing applications. The Company also holds top-three market positions in several related analytical instruments markets and is a leading provider of automated chemistry systems used in drug and chemical compound discovery and development. In addition, the Mettler-Toledo is the world’s largest manufacturer and marketer of metal detection systems used in production and packaging. Additional information about Mettler-Toledo can be found on its website www.mt.com

 

 

 

For more details, contact:

Sanjiv Arora
sanjiv@deeshapr.com
+91-22-32713357
Deesha Communications